Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 273 - 280 of 12011 results
A Circuit Win and the End of Chevron Deference Could Shift Tides in Drug Price Negotiation Program Challenges
February 13, 2025| Article| Viewpoint
Duplicate Discounts Between the 340B Program & Medicare Drug Price Negotiation Program
February 13, 2025| Article| Viewpoint
The IRA in 2025: The Future of Medicare Part D
February 13, 2025| Article| Viewpoint
From the Desk of ML Strategies: The Medicare Drug Price Negotiation Program Under the Second Trump Administration
February 13, 2025| Article| Viewpoint
Mintz IRA Update — Fourth Edition: Q1 2025
February 13, 2025| Article| Viewpoint
Trump Administration Seeks Public Comments for AI Action Plan — AI: The Washington Report
February 12, 2025| Article| Viewpoint
Watch Your Language! Non-Pro Rata Uptier Transactions and the Serta and Mitel Decisions
February 12, 2025| Blog| Viewpoint
Trump’s “Gender Ideology” Executive Order Meets the Workplace
February 12, 2025| Blog| Viewpoint
News & Press Releases
Mintz advised The Eagle Leasing Company, a leading provider of portable storage containers, ground level offices, semi-trailers, and mobile office solutions, in its acquisition by Rent-A-Container (RAC), a portfolio company of Kinderhook Industries, LLC.
Mintz’s Life Sciences practice has been shortlisted in multiple categories for the 2025 LMG Life Sciences Americas Awards. The winners will be announced at an awards ceremony in New York on September 4. In the United States, Mintz was shortlisted in the “Venture Capital Firm of the Year” category. In Canada, Mintz was shortlisted in the “Financial & Corporate Firm of the Year” and “Patent Strategy Firm of the Year” categories.
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|